Literature DB >> 28506189

Conducting Biobehavioral Research in Patients With Advanced Cancer: Recruitment Challenges and Solutions.

Stephanie Gilbertson-White1, Nicole Bohr1, Karen E Wickersham2.   

Abstract

Despite significant advances in cancer treatment and symptom management interventions over the last decade, patients continue to struggle with cancer-related symptoms. Adequate baseline and longitudinal data are crucial for designing interventions to improve patient quality of life and reduce symptom burden; however, recruitment of patients with advanced cancer in longitudinal research is difficult. Our purpose is to describe challenges and solutions to recruitment of patients with advanced cancer in two biobehavioral research studies examining cancer-related symptoms. Study 1: Symptom data and peripheral blood for markers of inflammation were collected from newly diagnosed patients receiving chemotherapy on the first day of therapy and every 3-4 weeks for up to 6 months. Study 2: Symptom data, blood, and skin biopsies were collected from cancer patients taking epidermal growth factor receptor inhibitors at specific time points over 4 months. Screening and recruitment results for both studies are summarized. Timing informed consent with baseline data collection prior to treatment initiation was a significant recruitment challenge for both the studies. Possible solutions include tailoring recruitment to fit clinic needs, increasing research staff availability during clinic hours, and adding recruitment sites. Identifying solutions to these challenges will permit the conduct of studies that may lead to identification of factors contributing to variability in symptoms and development of tailored patient interventions for patients with advanced cancer.

Entities:  

Keywords:  biobehavioral research; cancer; research study recruitment; symptoms

Mesh:

Substances:

Year:  2017        PMID: 28506189      PMCID: PMC5771405          DOI: 10.1177/1099800417709529

Source DB:  PubMed          Journal:  Biol Res Nurs        ISSN: 1099-8004            Impact factor:   2.522


  40 in total

Review 1.  Identifying, recruiting, and retaining seriously-ill patients and their caregivers in longitudinal research.

Authors:  Karen E Steinhauser; Elizabeth C Clipp; Judith C Hays; Maren Olsen; Robert Arnold; Nicholas A Christakis; Jennifer Hoff Lindquist; James A Tulsky
Journal:  Palliat Med       Date:  2006-12       Impact factor: 4.762

Review 2.  Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials.

Authors:  Carol A Townsley; Rita Selby; Lillian L Siu
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

3.  Epidermal growth factor receptor (EGFR) inhibitor-induced rash: a consecutive patient series that illustrates the need for rigorous palliative trials.

Authors:  Benjamin M Solomon; Aminah Jatoi
Journal:  J Palliat Med       Date:  2011-01-12       Impact factor: 2.947

4.  Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.

Authors:  Smita S Joshi; Sara Ortiz; Joslyn N Witherspoon; Alfred Rademaker; Dennis P West; Roger Anderson; Sara E Rosenbaum; Mario E Lacouture
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

5.  Treatment with oral anticancer agents: symptom severity and attribution, and interference with comorbidity management.

Authors:  Sandra L Spoelstra; Charles W Given; Alla Sikorskii; Atreyee Majumder; Monica Schueller; Barbara A Given
Journal:  Oncol Nurs Forum       Date:  2015-01       Impact factor: 2.172

6.  Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae.

Authors:  Lynne I Wagner; Mario E Lacouture
Journal:  Oncology (Williston Park)       Date:  2007-10       Impact factor: 2.990

7.  Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.

Authors:  Susan L Boone; Alfred Rademaker; Dachao Liu; Carmen Pfeiffer; David J Mauro; Mario E Lacouture
Journal:  Oncology       Date:  2007-12-21       Impact factor: 2.935

Review 8.  Using rare diseases as models for biobehavioral research: allergic bronchopulmonary aspergillosis.

Authors:  Paul A Greenberger; Carolyn B Yucha; Susan Janson; Karen Huss
Journal:  Allergy Asthma Proc       Date:  2007 Jul-Aug       Impact factor: 2.587

Review 9.  A systematic review of strategies used to increase recruitment of people with cancer or organ failure into clinical trials: implications for palliative care research.

Authors:  Jason Boland; David C Currow; Andrew Wilcock; Jennifer Tieman; Jamilla Akhter Hussain; Constantine Pitsillides; Amy P Abernethy; Miriam J Johnson
Journal:  J Pain Symptom Manage       Date:  2014-12-27       Impact factor: 3.612

Review 10.  Influences of cancer symptom knowledge, beliefs and barriers on cancer symptom presentation in relation to socioeconomic deprivation: a systematic review.

Authors:  Grace M McCutchan; Fiona Wood; Adrian Edwards; Rebecca Richards; Kate E Brain
Journal:  BMC Cancer       Date:  2015-12-23       Impact factor: 4.430

View more
  3 in total

1.  Understanding Symptom Burden in Patients With Advanced Cancer Living in Rural Areas.

Authors:  Stephanie Gilbertson-White; Yelena Perkhounkova; Seyedehtanaz Saeidzadeh; Maria Hein; Rachel Dahl; Andrean Simons-Burnett
Journal:  Oncol Nurs Forum       Date:  2019-07-01       Impact factor: 2.172

2.  Shared Decision-Making in Managing Breakthrough Cancer Pain in Patients With Advanced Cancer.

Authors:  Jeannine M Brant; Debra Wujcik; William N Dudley; Alison Petok; Brooke Worster; Diane Jones; Kim Bosket; Christian Brady; Carrie Tompkins Stricker
Journal:  J Adv Pract Oncol       Date:  2022-02-01

3.  Psychological distress of cancer patients caused by treatment delay during the COVID-19 pandemic in China: A cross-sectional study.

Authors:  Yingjun Ye; Jin Wang; Shuping Cai; Xiaowei Fu; Yongling Ji
Journal:  Psychooncology       Date:  2022-05-10       Impact factor: 3.955

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.